Study Summary
This trial looks into the effects of a drug on healthy men over 3 weeks.
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
3 Primary · 6 Secondary · Reporting Duration: Up to 45 days
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
MYK-224
1 of 1
Experimental Treatment
7 Total Participants · 1 Treatment Group
Primary Treatment: MYK-224 · No Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 55 · Male Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there any remaining opportunities to join this research endeavor?
"According to the clinicaltrials.gov webpage, this medical trial is still recruiting patients since its initial posting on January 16th of 2023 and last update in March 17th of same year." - Anonymous Online Contributor
Does the trial accept applicants aged sixty or above?
"This trial specifically seeks patients aged 18 to 55. However, there are 54 clinical studies available for minors and 368 trials targeting seniors." - Anonymous Online Contributor
How many participants are being welcomed into the experiment?
"Affirmative. The information posted on clinicaltrials.gov attests to this medical study's actively recruitment process, which was kickstarted on January 16th 2023 and recently updated March 17th 2023. 8 patients need to be sourced from a single location for the trial to commence." - Anonymous Online Contributor
Has MYK-224 been granted clearance by the FDA?
"Our team at Power gave MYK-224 a score of 1 due to the fact that this Phase 1 trial has only limited evidence backing its safety and efficacy." - Anonymous Online Contributor
Am I eligible to be a participant in this research endeavor?
"This trial is open to 8 individuals aged 18-55 who are in good health. Furthermore, these participants must have a documented LVEF of at least 60%, BMI between 18 and 32 kg/m^2, be male as determined by the investigator and sponsor, and possess acoustic windows that allow for accurate assessment of LV systolic activity from TTEs." - Anonymous Online Contributor